Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (241-250 of 283) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Cancer Research|February 13, 2023
Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple MyelomaLijun Yao, Julia T Wang, Reyka G Jayasinghe, et al.
Nature Communications|May 8, 2021
Co-evolution of tumor and immune cells during progression of multiple myelomaRuiyang Liu, Qingsong Gao, Steven M Foltz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 9, 2015
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term SurvivorsEvgeny Klyuchnikov, Ulrike Bacher, Nicolaus M Kröger, et al.
American Journal of Hematology|April 7, 2017
IgM myeloma: A multicenter retrospective study of 134 patientsJorge J Castillo, Artur Jurczyszyn, Lucie Brozova, et al.
American Journal of Hematology|September 25, 2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTHRobert Cornell, Parameswaran Hari, Shijie Tang, et al.
Nature Medicine|April 17, 2023
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trialZachary D Crees, Michael P Rettig, Reyka G Jayasinghe, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Pageof 29

Showing results (241-250 of 283) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Cancer Research|February 13, 2023
Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple MyelomaLijun Yao, Julia T Wang, Reyka G Jayasinghe, et al.
Nature Communications|May 8, 2021
Co-evolution of tumor and immune cells during progression of multiple myelomaRuiyang Liu, Qingsong Gao, Steven M Foltz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 9, 2015
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term SurvivorsEvgeny Klyuchnikov, Ulrike Bacher, Nicolaus M Kröger, et al.
American Journal of Hematology|April 7, 2017
IgM myeloma: A multicenter retrospective study of 134 patientsJorge J Castillo, Artur Jurczyszyn, Lucie Brozova, et al.
American Journal of Hematology|September 25, 2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTHRobert Cornell, Parameswaran Hari, Shijie Tang, et al.
Nature Medicine|April 17, 2023
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trialZachary D Crees, Michael P Rettig, Reyka G Jayasinghe, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Pageof 29